Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H Barrios

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
British Journal of Cancer|January 18, 2014
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinomaT E Hutson, R M Bukowski, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2016
Research needs in breast cancerF Cardoso, N Harbeck, C H Barrios, et al.
ESMO Open|January 28, 2026
Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancerK L Jhaveri, N M Iyengar, N C Turner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2021
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysisL A Emens, S Adams, C H Barrios, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of diseaseG Curigliano, X Hu, R Dent, et al.
British Journal of Cancer|July 1, 2015
Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancerP A Jänne, I Smith, G McWalter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2011
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastasesF Saad, J E Brown, C Van Poznak, et al.
ESMO Open|April 20, 2024
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trialT Powles, M Burotto, B Escudier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCCJ J Knox, C H Barrios, T M Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2025
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trialR J Motzer, B Escudier, M Burotto, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
British Journal of Cancer|January 18, 2014
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinomaT E Hutson, R M Bukowski, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2016
Research needs in breast cancerF Cardoso, N Harbeck, C H Barrios, et al.
ESMO Open|January 28, 2026
Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancerK L Jhaveri, N M Iyengar, N C Turner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2021
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysisL A Emens, S Adams, C H Barrios, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of diseaseG Curigliano, X Hu, R Dent, et al.
British Journal of Cancer|July 1, 2015
Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancerP A Jänne, I Smith, G McWalter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2011
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastasesF Saad, J E Brown, C Van Poznak, et al.
ESMO Open|April 20, 2024
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trialT Powles, M Burotto, B Escudier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCCJ J Knox, C H Barrios, T M Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2025
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trialR J Motzer, B Escudier, M Burotto, et al.
Pageof 3